
"May 19, 2023",Moderna reports ‘encouraging’ early data for one of its rare disease medicines,0
"Updated May 19, 2023","Teva puts rival to Prometheus, Pfizer drugs at center of turnaround plans",0
"May 17, 2023",PTC’s drug for PKU succeeds in late-stage clinical trial,0
"May 17, 2023",Roche pushes forward with MS drug amid rivals’ setbacks,0
"Updated May 16, 2023",Gene therapy consortium targets eight rare diseases for clinical trials,0
"May 12, 2023","Sanofi, AstraZeneca study results add support for their RSV drug in infants",0
"May 10, 2023","Alzheimer’s doctors see promise, limits in Lilly’s latest drug data",0
"May 9, 2023",Roche pays China-based biotech $70M for a new HER2 drug,0
"May 5, 2023",FibroGen’s anemia pill falls short in blood cancer study,0
"May 4, 2023","Valneva, Pfizer push back timeline for Lyme disease vaccine",0
"May 3, 2023",Lilly’s new Alzheimer’s data may both help and hinder rival Biogen,0
"Updated May 3, 2023",Lilly drug slows Alzheimer’s decline in large study,0
"May 2, 2023",Travere set back by study failure of kidney disease drug,0
"April 27, 2023","Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle",0
"April 27, 2023",Lilly drug Mounjaro succeeds in second weight loss study,0
"April 25, 2023",Novartis trims 10% of drug pipeline in research cutback,0
"Updated April 25, 2023",Morphic shares swing on study data for drug viewed as ‘oral Entyvio’,0
"April 24, 2023","Ionis, AstraZeneca detail data backing rare disease rival to Alnylam drugs",0
"April 21, 2023",Apellis’ immune system drug hits a setback in ALS,0
"April 19, 2023",J&J study data show dramatic benefit to multiple myeloma cell therapy,0
"Updated May 3, 2023",Vaxcyte strengthens case for experimental pneumococcal vaccine,0
"April 16, 2023","Moderna, Merck data support claim of cancer vaccine’s promise",0
"April 11, 2023",New data raise more doubts about Moderna’s flu vaccine,0
"April 7, 2023","Merck, Eisai report pair of study setbacks for cancer drug combo",0
"Updated April 6, 2023","In NEJM, full Pfizer data show RSV vaccine’s protection",0
"March 31, 2023",Cytokinetics to end late-stage study of ALS drug,0
"Updated March 29, 2023",J&J abandons RSV vaccine in major strategy shift,0
"March 28, 2023",Viking joins obesity drug development race with early study data,0
"March 28, 2023",Intra-Cellular shares rise on depression study’s success,0
"March 27, 2023","Novartis, following Lilly, claims success in early breast cancer study",0
"Updated March 31, 2023","ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein",0
"March 23, 2023","Sanofi, Regeneron surge as Dupixent scores in COPD trial",0
"Updated March 20, 2023",Karuna’s schizophrenia drug succeeds in a second late-stage trial,0
"March 18, 2023","Takeda, chasing Bristol Myers, unveils awaited TYK2 drug data",0
"March 17, 2023","Merck TIGIT drug misses goal in lung cancer trial, adding to doubts over approach",0
"March 13, 2023",Clinical trial researchers are burned out too. Automated data capture is helping.,0
"March 10, 2023",FDA advisers back earlier use of Roche lymphoma drug,0
"March 9, 2023",Lilly reaches end of the road with long-studied Alzheimer’s drug,0
"March 9, 2023",AstraZeneca builds on study successes in early lung cancer,0
"March 7, 2023","With PCSK9 pill, Merck aims to succeed where others failed",0
"March 6, 2023",Merck drug data suggest ‘new direction’ for rare blood vessel disease,0
"March 6, 2023",Esperion shares sink on highly anticipated heart drug results,0
"March 6, 2023",BridgeBio shares jump on dwarfism drug data,0
"March 3, 2023",Exelixis reports trial failure for cancer drug combination,0
"March 3, 2023","Despite study setback, a biotech plans to push tremor drug into late-stage testing",0
"March 2, 2023",FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs,0
"March 2, 2023","Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients",0
"Feb. 28, 2023",Merck reports two Phase 3 study misses for Keytruda,0
"Feb. 28, 2023","Following another trial failure, a brain biotech considers ‘strategic alternatives’",0
"Feb. 23, 2023",Sickle cell pipeline narrows as gene therapy developers rethink research plans,0
"Feb. 21, 2023",Merck’s COVID-19 treatment falls short in prevention study,0
"Feb. 17, 2023",Pfizer makes case for PARP-blocking drug in prostate cancer,0
"Feb. 17, 2023","Pfizer, Valneva remove half of participants from study of Lyme disease shot",0
"Feb. 10, 2023",Pfizer begins plan to challenge Shingrix with an mRNA vaccine,0
"Feb. 9, 2023",Galapagos nixes EU approval plans after top drug fails in late-stage study,0
"Feb. 8, 2023",Bayer begins key tests for closely watched blood thinner,0
"Feb. 7, 2023",Roche rival to AstraZeneca’s Soliris succeeds in late-stage testing,0
"Feb. 6, 2023",J&J says drug it acquired from Momenta succeeds in study of ultra-rare condition,0
"Feb. 6, 2023",Idorsia shares sink on ‘unexpected’ failure of drug study,0
"Feb. 2, 2023",GSK moves hepatitis B drug into late-stage testing,0
"Feb. 1, 2023",Novartis confirms it has stopped development of experimental Huntington’s drug,0
"Jan. 27, 2023","J&J, Legend’s cancer cell therapy has early success in key clinical trial",0
"Updated Jan. 26, 2023",Magenta halts study of targeted conditioning drug after participant’s death,0
"Jan. 26, 2023",Bristol Myers says CAR-T therapy curbed leukemia in long-running study,0
"Jan. 25, 2023","Merck reports one success, one setback from late-stage Keytruda trials",0
"Jan. 23, 2023",Pliant shares jump on new data for lung disease drug,0
"Jan. 19, 2023",Roche says Tecentriq immunotherapy reduces risk of liver cancer recurrence,0
"Jan. 18, 2023","Moderna reports positive RSV vaccine results, pressuring Pfizer, GSK",0
"Jan. 18, 2023",Large study of J&J’s HIV vaccine stopped after shot found ineffective,0
"Updated Jan. 6, 2023","FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision",0
"Jan. 5, 2023",Novocure shares soar on positive lung cancer data,0
"Jan. 4, 2023","Roivant reveals positive data for IBD drug, intensifying rivalry with Prometheus",0
"Jan. 3, 2023",10 clinical trials to watch in the first half of 2023,0
"Dec. 21, 2022","Pfizer advances diabetes, obesity drug hopeful into mid-stage testing",0
"Dec. 20, 2022",FDA halts planned trial of Entrada Duchenne drug,0
"Dec. 20, 2022","Doubts around cancer drug target persist after Gilead, Arcus study results offer ‘mixed picture’",0
"Dec. 20, 2022",Government spending bill would tighten FDA oversight of accelerated drug approvals,0
"Dec. 19, 2022",Madrigal shares triple on positive NASH study results,0
"Dec. 15, 2022",Third Harmonic halts study of lead drug over safety risk,0
"Dec. 14, 2022",Kymera shares jump on Sanofi’s decision to advance protein-degrading drug,0
"Dec. 13, 2022",Moderna vaccine succeeds in early-stage skin cancer study with Merck’s Keytruda,0
"Dec. 12, 2022","At ASH, Regeneron plays catch-up with its next cancer drugs",0
"Updated Dec. 12, 2022","J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways",0
"Updated Dec. 15, 2022",[Podcast] Thinking Big for Small and Mid-Sized Biotechs,0
"Dec. 9, 2022","Pharvaris, pushing through trial pause, sees shares surge with new study results",0
"Dec. 8, 2022",Novartis gets second trial win for blockbuster hopeful,0
"Dec. 8, 2022",Relmada sinks further as depression drug fails second large trial,0
"Dec. 7, 2022",Prometheus shares soar on new data for inflammation drug,0
"Dec. 7, 2022","Esperion, without data, says cholesterol pill lowered heart risk in study",0
"Dec. 6, 2022","MEI, Kyowa stop lymphoma drug trials after FDA meeting",0
"Dec. 5, 2022",Novartis prostate cancer drug succeeds in study key to company’s sales hopes,0
"Dec. 5, 2022","With new data, Nkarta builds case for ‘natural killer’ cell therapy",0
"Dec. 1, 2022",Roche study failure gives Alzheimer’s researchers new clues in drug quest,0
"Dec. 1, 2022",Lilly’s Alzheimer’s drug bests Aduhelm in plaque clearance study,0
"Nov. 29, 2022",What to make of Eisai and Biogen’s Alzheimer’s drug results,0
"Nov. 28, 2022",CinCor shares dive after blood pressure drug fails key trial,0
"Nov. 28, 2022",Axsome says drug eased Alzheimer’s symptom in positive study,0
"Nov. 28, 2022",FDA grants speedy review to Sarepta’s Duchenne gene therapy,0
"Nov. 21, 2022","A unified, connected foundation is transforming the future of digital trials",0
"Nov. 17, 2022",Editas to seek partner for CRISPR medicine after lackluster study results,0
"Nov. 14, 2022",Moderna data supports use of omicron booster over original vaccine,0
"Nov. 14, 2022",Trial failures end latest hope for Roche’s Alzheimer’s drug,0
"Nov. 8, 2022",Early data hint at benefit for Amgen’s obesity drug,0
"Nov. 7, 2022",GSK myeloma drug comes up short in confirmatory test,0
"Nov. 7, 2022",Amgen to test new way to lower heart risk with large drug trial,0
"Nov. 4, 2022",Bispecific cancer drugs and gene therapy advances: What to watch at this year’s ASH meeting,0
"Nov. 3, 2022",Abeona to submit cell therapy for approval after positive results for skin disorder treatment,0
"Nov. 1, 2022",Pfizer gets first positive result for an RSV vaccine in pregnant women,0
"Oct. 31, 2022","With positive trial results, Bristol Myers looks to widen use of blood disease drug",0
"Oct. 27, 2022",GSK shelves filing plans for arthritis drug after trial results,0
"Oct. 26, 2022",AstraZeneca extends run of trial successes with breast cancer drug results,0
"Oct. 24, 2022",Vaxcyte rides investor enthusiasm for early pneumococcal vaccine data,0
"Oct. 24, 2022",Novartis rival to AstraZeneca rare disease drugs succeeds in study,0
"Updated Oct. 19, 2022",FDA advisers back withdrawal of controversial drug for preterm birth,0
"Oct. 17, 2022",NGM shares plunge as Merck-partnered eye drug fails Phase 2 test,0
"Oct. 13, 2022",GSK sets high bar with trial results for RSV vaccine,0
"Oct. 13, 2022",Relmada shares collapse after fast-acting depression drug fails first test,0
"Oct. 11, 2022","Vertex, after setbacks, moves forward with second-generation rare disease drug",0
"Oct. 11, 2022",A young biotech’s shares soar on early psoriasis drug results,0
"Oct. 10, 2022","Merck cardiovascular drug succeeds in study, validating $11B buyout bet",0
"Oct. 10, 2022",Cytokinetics pushes on with late-stage study of ALS drug,0
"Oct. 7, 2022",Allogene starts first pivotal trials of an ‘off-the-shelf’ cell therapy for cancer,0
"Oct. 5, 2022",GSK immunotherapy matches Keytruda in lung cancer trial,0
"Oct. 4, 2022",Pfizer says PARP inhibitor succeeds in prostate cancer study,0
"Oct. 4, 2022",KalVista stops work on rare disease drug over safety concerns,0
"Oct. 3, 2022","Biogen, Denali begin late-stage testing of Parkinson’s drug",0
"Sept. 30, 2022",[PODCAST] Evolution and Innovation in Oncology Therapeutics Development,0
"Sept. 29, 2022",Biohaven’s ALS drug comes up short in Mass General trial,0
"Sept. 29, 2022","With little data to go on, experts question how useful Eisai, Biogen’s new Alzheimer’s drug will be",0
"Sept. 28, 2022","Biogen, Eisai data raises hope for other experimental Alzheimer’s drugs",0
"Updated Sept. 27, 2022","In surprise result, Alzheimer’s drug from Eisai, Biogen shows benefit in large trial",0
"Sept. 23, 2022","Pfizer, Sangamo set to resume gene therapy study after safety delay",0
"Sept. 23, 2022",AstraZeneca gives up on Ionis’ RNA drug for heart disease,0
"Sept. 20, 2022","Merck to resume testing of closely watched HIV drug, but at lower dose",0
"Sept. 16, 2022",AstraZeneca claims positive results for its “add-on” drug for rare blood disease,0
"Updated Sept. 16, 2022",Intellia offers first look at CRISPR drug for rare swelling disorder,0
"Sept. 15, 2022",Pfizer reports success in trial of all-in-one meningitis vaccine,0
"Sept. 13, 2022",Akero shares soar as NASH drug succeeds in mid-stage trial,0
"Sept. 12, 2022","Amgen data supports KRAS cancer drug, but survival benefit remains in question",0
"Sept. 9, 2022",FDA names new head to vaccine review office,0
"Sept. 8, 2022",Regeneron answers rivals with data for new version of top-selling eye drug,0
"Sept. 8, 2022",Gilead says its breast cancer drug helped patients live longer in study,0
"Sept. 8, 2022",Relay impresses with early study data for targeted cancer drug,0
"Sept. 8, 2022",Alnylam details anticipated results from heart disease drug trial,0
"Sept. 6, 2022",Iveric readies eye drug for FDA following study success,0
"Sept. 6, 2022",Sarepta to restart Duchenne drug study after FDA lifts hold,0
"Aug. 31, 2022",Amgen says KRAS drug beat chemo in lung cancer study,0
"Aug. 30, 2022",Jounce’s latest setback dampens outlook for another cancer immunotherapy target,0
"Aug. 29, 2022","AstraZeneca, matching Lilly, reports positive heart failure data for diabetes pill",0
"Aug. 29, 2022","Bristol Myers, Bayer study results seed doubt about an emerging group of blood thinners",0
"Aug. 25, 2022",Pfizer follows GSK with positive Phase 3 results for RSV vaccine,0
"Aug. 24, 2022",Safety worries spur Novartis to suspend drug dosing in Huntington’s trial,0
"Aug. 23, 2022",Biotech Erasca taps MD Anderson to help advance cancer drug work,0
"Aug. 22, 2022",Pharvaris studies of rare disease drug put on hold by FDA,0
"Aug. 18, 2022",CSL says drug for rare swelling disorder succeeds in late-stage study,0
"Updated Aug. 17, 2022",Blueprint drug succeeds in rare disease study important to its market prospects,0
"Aug. 16, 2022",Ventyx touts early data for potential rival to Bristol Myers psoriasis drug,0
"Aug. 15, 2022",Novartis bid to repurpose rare disease drug for cancer falls short in third trial,0
"Aug. 10, 2022",Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma,0
"Aug. 9, 2022","Pfizer, Valneva take next step with Lyme disease shot, starting large trial",0
"Aug. 9, 2022","Fresh off Enhertu success, AstraZeneca and Daiichi claim progress for next cancer drug",0
"Aug. 8, 2022","Amgen data on KRAS cancer drug disappoints, opening door for rival Mirati",0
"Aug. 5, 2022",Lilly takes long view on Alzheimer’s drug as FDA starts expedited review,0
"Aug. 3, 2022","Alnylam drug succeeds in key heart disease study, boosting company",0
"Aug. 1, 2022",The promise of oral therapies for cytokine inhibition,0
"July 28, 2022",Alnylam reveals longer wait for anticipated drug trial results,0
"July 27, 2022","Pfizer, BioNTech to study 'bivalent' booster as FDA weighs approach",0
"July 26, 2022",BridgeBio advances drug for dwarfism after study data,0
"July 26, 2022","Seagen, Astellas claim positive results in study key to cancer drug's success",0
"July 22, 2022",Vertex to move non-opioid painkiller into late-stage tests after FDA agreement,0
"July 13, 2022",Atara shares sink after update on multiple sclerosis trial,0
"July 11, 2022","With new data, Pliant drug shows promise in tough-to-treat lung disease",0
"July 7, 2022",New analysis encourages Intercept to refile NASH drug for approval,0
"July 6, 2022","FDA, under fire for Aduhelm approval, starts review of another Alzheimer's drug",0
"July 5, 2022",10 clinical trials to watch in the second half of 2022,0
"July 1, 2022","Celldex, continuing comeback, adds to early promise for skin disease drug",0
"June 30, 2022","FDA halts tests of Sanofi drug, acquired in $3.7B buyout, due to side effects",0
"Updated June 29, 2022",Jazz drug fails in late-stage study for multiple sclerosis,0
"June 24, 2022","Sanofi, GSK say dual-acting vaccine prevents COVID-19 from omicron in large trial",0
"June 23, 2022",FDA suspends US testing of Sarepta Duchenne drug over safety concerns,0
"June 23, 2022",UniQure buoyed by early data for Huntington's gene therapy,0
"June 22, 2022","Biogen, citing insurance challenges, shutters one of its Aduhelm studies",0
"June 21, 2022",Mixed results for PTC Duchenne drug put spotlight on EU approval,0
"June 21, 2022","Ionis, AstraZeneca claim success for competitor to Alnylam rare disease drug",0
"June 16, 2022",Roche Alzheimer's study fails in another setback to a long-tested hypothesis,0
"June 15, 2022",Pfizer study results show Paxlovid benefit less clear in lower-risk patients,0
"June 13, 2022","FDA staff supportive of Pfizer, Moderna COVID vaccines in young children",0
"June 11, 2022","Vertex, CRISPR strengthen case for pioneering gene-editing treatment",0
"June 10, 2022",GSK claims first positive Phase 3 result for an RSV vaccine,0
"June 10, 2022",Latest Caribou data add to 'off-the-shelf' cell therapy's durability questions,0
"June 9, 2022",Alnylam follows rivals with new study results for kidney disease drug,0
"June 8, 2022",Moderna says 'bivalent' booster sparks stronger immune response against omicron,0
"June 7, 2022",Roche keeps the faith in new cancer immunotherapy despite trial setbacks,0
"June 6, 2022","ASCO 2022: Gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy",0
"June 5, 2022","'Dramatic' study results for AstraZeneca, Daiichi drug suggest new way to treat aggressive breast cancer",0
"June 4, 2022",Detailed study data show modest benefit to Gilead breast cancer drug,0
"June 1, 2022",Bristol Myers' autoimmune drug shows potential in lupus,0
"June 1, 2022","Sage, Biogen drug meets goal in postpartum depression study",0
"May 27, 2022",Adicet data hints at early promise for 'gamma delta' cell therapy,0
"May 26, 2022",Merck study results signal blood cancer potential for new type of immunotherapy,0
"Updated May 27, 2022",Mirati matches Amgen with updated data for KRAS-blocking cancer drug,0
"May 26, 2022",3 cancer drug studies to watch at next month's ASCO meeting,0
"May 24, 2022","Responding to outbreak, Moderna starts early work on monkeypox vaccine",0
"May 24, 2022",Springworks shares fall despite drug trial's success,0
"May 24, 2022","Pfizer, Lilly bolster cases for experimental ulcerative colitis drugs",0
"May 23, 2022",Pfizer says 3 doses of its COVID-19 vaccine works in youngest children,0
"May 23, 2022",Biohaven hits setback as it moves beyond migraine,0
"May 23, 2022","Concert drug helps regrow hair in study, boosting shares",0
"May 19, 2022",Trial setback casts doubt on a biotech's respiratory virus drug,0
"Updated May 18, 2022",Scientists home in on cause of Duchenne gene therapy side effect,0
"May 17, 2022","Gilead, having resolved manufacturing issues, forges ahead with HIV drug",0
"May 16, 2022",Bristol Myers' Opdivo comes up short in bladder cancer trial,0
"May 12, 2022",Key Bristol Myers drug holds up in long-term psoriasis study,0
"May 11, 2022","In first, Verve gets clearance to test base editing inside the body",0
"May 11, 2022","Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class",0
"May 9, 2022","J&J ends hepatitis B, HPV vaccine work with Bavarian Nordic",0
"May 5, 2022","Argenx drug succeeds in trial, beats sales forecasts",0
"May 3, 2022",Pfizer cleared to restart hemophilia gene therapy trial,0
"May 2, 2022",FDA rejects two China-developed cancer drugs,0
"May 2, 2022",Vertex surprised by FDA halt of diabetes cell therapy study,0
"May 2, 2022","Ionis, AstraZeneca change a key trial, fueling more questions about a genetic heart disease",0
"April 28, 2022",Lilly's closely watched diabetes drug scores in obesity trial,0
"April 25, 2022",Roche stumbles in latest setback for an emerging group of breast cancer drugs,0
"April 25, 2022",How a surprise finding made an Alnylam study one of biotech's most 'polarizing' trials,0
"April 22, 2022",FDA panel supports agency push to raise approval bar for certain cancer drugs,0
"April 18, 2022",Bristol Myers scraps $2B Nektar partnership after trial failures,0
"April 14, 2022","AbbVie, Genmab, with new data, prep FDA application for dual-acting cancer drug",0
"April 12, 2022",FDA clears Gilead to restart some studies of top cancer drug,0
"April 11, 2022","AACR 2022: NK cell promise, more TIGIT questions and extending CAR-T's reach",0
"Updated Feb. 9, 2023",[Podcast] Breaking Down Barriers: How Bladder Cancer Innovations Benefit Patients and Treatments for Other Diseases,0
"March 31, 2022",Vertex gets positive trial results for non-opioid painkiller in boost to pipeline,0
"Updated March 30, 2022","FDA advisers narrowly side against an experimental ALS drug, likely lowering its approval chances",0
"March 30, 2022","Adagio plans comeback for COVID drug, but is it too late?",0
"March 30, 2022",Roche's top immunotherapy prospect fails study in tough-to-treat lung cancer,0
"March 29, 2022",Pfizer inflammatory disease drug hits goal in second study,0
"March 28, 2022",How a long shot ALS drug came before the FDA,0
"March 28, 2022",Biogen shelves ALS drug after early-stage trial failure,0
"March 25, 2022","FDA rebuffs MEI, Kyowa Kirin as another cancer drug class draws scrutiny",0
"March 23, 2022",Pfizer claims study success for drug key to Arena buyout,0
"March 23, 2022","Moderna, with new data, to seek clearance for COVID-19 vaccine in young children",0
"March 22, 2022",Argenx boosted by positive trial results for new shot,0
"Updated March 22, 2022",Vertex plans path to FDA for top drug prospect,0
"March 17, 2022",How Merck's 'puzzling' results could impact immunotherapy's role in early lung cancer,0
"March 16, 2022","With trial success in kidney disease, Lilly, Boehringer make case for broader use of diabetes drug",0
"March 14, 2022",BridgeBio looks for comeback with trial results for muscular dystrophy drug,0
"March 14, 2022","Nektar, Bristol Myers drug combination fails in late-stage melanoma trial",0
"March 9, 2022","Sanofi, with positive data in hand, to ask for approval of longer-lasting hemophilia therapy",0
"March 9, 2022",Pfizer to test COVID pill in children as vaccinations in US plateau,0
"March 7, 2022",Bluebird's CFO resigns as cash woes raise doubts about its future,0
"March 7, 2022","Gilead says breast cancer drug succeeded in key study, but offers few details",0
"March 3, 2022","Roche, nearing major trial readouts, starts new Alzheimer's drug study",0
"Updated Feb. 28, 2022",Intellia presses forward with new results for pioneering CRISPR drug,0
"Feb. 28, 2022",FDA rejects Reata drug for rare kidney disease,0
"Feb. 24, 2022","Moderna bets on booster demand, advancing new 'bivalent' COVID-19 shot",0
"Feb. 24, 2022","Allogene, slipping in 'off-the-shelf' CAR-T race, prepares for key trials",0
"Feb. 23, 2022","Sanofi and GSK, after delays, to seek clearance for COVID-19 vaccine",0
"Feb. 23, 2022",Kodiak crashes on negative trial results for would-be Eylea competitor,0
"Updated Feb. 23, 2022","AstraZeneca, Daiichi press rivals with new results for breast cancer drug",0
"Feb. 18, 2022","Citing safety signal, GSK pauses some trials of new RSV vaccine",0
"Feb. 16, 2022","Sage claims new data show depression drug works, but doubts remain",0
"Updated Feb. 15, 2022","Califf confirmed as FDA chief in close vote, ending protracted vacancy at health agency",0
"Feb. 15, 2022",Amgen sees potential for KRAS drug in treating pancreatic cancer,0
"Feb. 14, 2022",EMA follows FDA in scrutinizing safety of certain immune drugs,0
"Feb. 11, 2022","ProQR eye drug comes up short in key study, surprising company and investors",0
"Feb. 10, 2022",Pfizer aims to restart late-stage trial of Duchenne gene therapy following safety setback,0
"Updated Feb. 14, 2022",Pressure rises as Gilead awaits important study results for top cancer drug,0
"Feb. 1, 2022",The pipeline of new antibiotics is drying up. A bill in Congress aims to change that.,0
"Jan. 31, 2022",Madrigal adds to safety data for NASH drug,0
"Jan. 28, 2022","Regeneron, Sanofi are latest to withdraw a cancer drug application",0
"Jan. 26, 2022",Moderna follows Pfizer in beginning trial of omicron vaccine,0
"Jan. 26, 2022",Cortexyme to shift focus after FDA places hold on experimental Alzheimer's drug,0
"Jan. 25, 2022","With new trial, Pfizer and BioNTech will test whether an omicron vaccine is needed",0
"Jan. 25, 2022",Sierra Oncology records success in late-stage study of bone cancer drug,0
"Jan. 21, 2022",Roche sees cause for optimism with failed Huntington's disease drug. Others aren't so sure.,0
"Jan. 21, 2022","Alnylam, awaiting key study data, builds case for its next rare disease drug",0
"Jan. 19, 2022",EQRx builds case for cancer drug it hopes can disrupt market,0
"Jan. 18, 2022",Roche revives a closely watched Huntington's disease drug,0
"Updated Jan. 11, 2022",Medicare proposes to limit coverage of Biogen Alzheimer's drug,0
"Jan. 10, 2022",Allogene cleared by FDA to resume 'off the shelf' cancer cell therapy trials,0
"Updated Jan. 10, 2022",BioMarin plans return to FDA with updated data on hemophilia gene therapy,0
"Jan. 4, 2022",Avrobio stops work on rare disease gene therapy after unexpected study results,0
"Updated Jan. 6, 2022",10 clinical trials to watch in the first half of 2022,0
"Dec. 22, 2021",Allakos shares plunge as company's top drug falls short in studies,0
"Dec. 22, 2021","Gilead, following Merck, hits its own safety setback in HIV",0
"Dec. 21, 2021",Duchenne patient dies in Pfizer gene therapy study,0
"Dec. 16, 2021",EU regulator says member countries can use Pfizer's experimental COVID pill,0
"Dec. 16, 2021",Biogen reserves four years for trial meant to confirm its Alzheimer's drug works,0
"Dec. 15, 2021","Sanofi, GSK say COVID vaccine works as booster, but delay key study results",0
"Dec. 14, 2021",Two cancer cell therapy studies succeeded. Why did a third fail?,0
"Dec. 14, 2021","In final analysis, Pfizer's COVID-19 pill remains highly effective",0
"Dec. 14, 2021","Rebounding from setbacks, Sanofi reveals promising data for hemophilia drug",0
"Dec. 13, 2021","On the hunt for new ALS drugs, researchers see progress, and a long road ahead",0
"Updated Dec. 13, 2021",CAR-T therapy trials show promise for earlier use in lymphoma,0
"Dec. 10, 2021",Moderna reveals first study results for seasonal flu vaccine,0
"Dec. 10, 2021",Latest Roche results show promise for new type of cancer immunotherapy,0
"Dec. 9, 2021",Fresh data show UniQure's hemophilia gene therapy appears to hold up,0
"Dec. 7, 2021","Vaccine from Medicago, GSK protective against COVID-19 in large study",0
"Dec. 7, 2021",Acadia shares rise on study success for Rett syndrome drug,0
"Dec. 1, 2021","Vertex, needing research spark, finds promising results in small study of kidney disease drug",0
"Nov. 24, 2021","With safety a concern, Merck, Gilead pause study of HIV drugs",0
"Nov. 19, 2021",A worrisome safety signal slows Merck's HIV ambitions,0
"Nov. 18, 2021",FDA approves Merck's Keytruda as first immunotherapy for early kidney cancer,0
"Nov. 12, 2021",Cortexyme plans path forward for Alzheimer's drug that failed study,0
"Nov. 11, 2021",Detailed Roche study results muddy another Alzheimer's hypothesis,0
"Updated Nov. 8, 2021",Mirati gives first look at KRAS drug combination in lung cancer,0
"Nov. 8, 2021",Clinical trials face increasing challenges,0
"Nov. 5, 2021",Pfizer pill for COVID-19 shows dramatic benefit in major study finding,0
"Oct. 26, 2021","Cortexyme drug fails in Alzheimer's trial, but company sees validation of unorthodox approach",0
"Updated Nov. 8, 2021",Novartis hits another setback in plan to repurpose rare disease drug in lung cancer,0
"Oct. 18, 2021",Biogen's closely watched ALS drug comes up short in late-stage study,0
"Updated Oct. 13, 2021",CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T,0
"Oct. 11, 2021",Sarepta outlines final push for Duchenne gene therapy,0
"Oct. 8, 2021",Relay’s targeted cancer drug could be safer than its competitors. Is it more effective?,0
"Updated Oct. 8, 2021",Allogene cell therapy trials halted by FDA after unexpected safety finding,0
"Oct. 6, 2021",Takeda halts studies of touted sleep disorder drug over safety concern,0
"Oct. 5, 2021",Collins to step down as NIH head in transition for research agency,0
"Oct. 4, 2021",J&J heats up RSV race with new vaccine data,0
"Oct. 4, 2021",Sarepta embarks on late-stage clinical trial of Duchenne gene therapy,0
"Oct. 1, 2021","Merck says antiviral pill effective against COVID-19, lifting hopes for first oral drug",0
"Sept. 29, 2021","After long wait, Editas reveals first data for CRISPR gene editing treatment",0
"Sept. 28, 2021","Sanofi claims positive early data for mRNA COVID shot, but pivots to flu instead",0
"Sept. 27, 2021","As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial",0
"Sept. 22, 2021",Chinese drugmaker Clover says vaccine prevents COVID-19 in large trial,0
"Sept. 20, 2021",Pfizer says coronavirus vaccine is safe and spurs immune response in children,0
"Updated Sept. 21, 2021","ESMO21: Mirati sets new KRAS bar, AstraZeneca's breast cancer data and Keytruda challengers line up",0
"Sept. 17, 2021",Biogen says experimental pain drug helps neuropathy patients in mid-stage trial,0
"Sept. 16, 2021",Amgen to advance KRAS drug combination after improved results in colon cancer,0
"Sept. 15, 2021","New data from Israel, Pfizer show potent effect from third coronavirus shot",0
"Updated Sept. 10, 2021","Apellis eye drug succeeds in one key study, but falls short in its twin",0
"Sept. 9, 2021","Sanofi drug for rare skin disease, acquired in buyout, fails in late-stage trial",0
"Sept. 8, 2021","Autism drug fails in late-stage trials, Servier says",0
"Sept. 1, 2021","Pfizer, Merck launch large new trials of oral COVID-19 drugs",0
"Aug. 31, 2021",Hint of benefit in Alzheimer's drug study fuel stock surge for Swiss biotech,0
"Aug. 30, 2021","Pfizer drug bests Sanofi, Regeneron's Dupixent in head-to-head study",0
"Aug. 26, 2021",AstraZeneca reports study success for rare disease drug acquired in Alexion deal,0
"Aug. 24, 2021","With new results, J&J's $1B gamble on a targeted inflammation drug faces long odds",0
"Aug. 23, 2021",Alexion discontinues ALS drug trial due to 'lack of efficacy',0
"Aug. 16, 2021",Lilly's new eczema drug scores in late-stage studies,0
"Aug. 9, 2021",Roche sets bar in early lymphoma treatment with Polivy study results,0
"Aug. 5, 2021","Regeneron drug extends survival in lung cancer trial, lifting company's hopes in field",0
"Aug. 3, 2021",FDA allows Novartis gene therapy trials to resume after nearly 2 year pause,0
"July 30, 2021",Pfizer's fast progress shines spotlight on an emerging vaccine race,0
"July 27, 2021","Biogen, Ionis tout data from early study of RNA-based Alzheimer's drug",0
"July 26, 2021",Denali drug for rare brain disease disappoints investors,0
"July 22, 2021","Seres, after earlier success, fails a key test for microbiome drugs",0
"July 19, 2021","Cytokinetics heart drug succeeds in mid-stage study, boosting shares",0
"July 15, 2021",Merck details an immunotherapy 'milestone' in early breast cancer,0
"July 9, 2021",Celldex pins its hopes for a comeback on skin disease drug,0
"July 7, 2021",Moderna puts seasonal flu vaccine ambitions to the test,0
"July 6, 2021","As Arrowhead falters, lungs remain a tough target for RNA drugs",0
"July 6, 2021","Lilly, Boehringer say diabetes drug first to succeed in hard-to-treat heart failure",0
"July 1, 2021",CureVac vows to seek vaccine approval despite low efficacy in COVID-19 study,0
"June 30, 2021",Roche partner sees promise for anti-COVID 19 pill in early study,0
"June 29, 2021",Pfizer's neuroscience spinout scores in schizophrenia,0
"June 28, 2021",Gilead matches Bristol Myers in showing benefit to earlier CAR-T treatment,0
"June 26, 2021","Intellia, with first results, delivers a 'landmark' for CRISPR gene editing",0
"June 25, 2021",FDA advisers vote down Incyte cancer drug as agency takes tougher line,0
"June 24, 2021","Arcus claims positive study results for lung cancer drug, but shares no details",0
"June 22, 2021","A year after getting UniQure's gene therapy, hemophilia patients are still doing better",0
"June 22, 2021",Merck says Keytruda extends survival in cervical cancer study,0
"June 21, 2021",Long-term Zolgensma data backs up gene therapy's use in youngest patients,0
"June 21, 2021","GSK, Vir build case for COVID-19 antibody drug with new study data",0
"June 21, 2021",8 key clinical trials to watch for the rest of 2021,0
"June 18, 2021",US to invest $3B in research quest for COVID-19 pill,0
"June 17, 2021",Trial failure dashes Biogen hopes for next Alzheimer's drug,0
"June 16, 2021",Regeneron antibody cuts risk of COVID-19 death in UK study,0
"June 15, 2021",Biogen gene therapy deal has yet to bear fruit,0
"Updated June 15, 2021","Sage antidepressant succeeds in key study, but data raise questions",0
"Updated June 14, 2021",Novavax says vaccine 90% effective against COVID-19 in large trial,0
"Updated June 11, 2021",Vertex stops work on second rare disease drug after study results disappoint,0
"June 9, 2021",Beigene expands into cancer cell therapy with Shoreline pact,0
"June 9, 2021",Biogen Alzheimer's approval could open the door for similar drugs,0
"Updated June 9, 2021",The FDA approved Biogen's Alzheimer's drug. The company now has years to confirm it works.,0
"June 7, 2021","ASCO21: An immunotherapy debate, an NK cell question and the next precision drugs",0
"June 3, 2021","An AstraZeneca, Merck drug slows the return of genetic breast cancer. Will testing speed up?",0
"June 3, 2021",Novartis prostate cancer drug extends survival in key test of radiopharmaceutical therapy,0
"June 1, 2021",Sanofi rare disease drug hits another setback,0
"May 27, 2021",UniQure moves Huntington's gene therapy to next phase of key trial,0
"May 27, 2021",'A hugely consequential decision:' How Biogen's Alzheimer's drug came to face the FDA,0
"May 25, 2021","Moderna, with new results, set to seek vaccine clearance for young teens",0
"May 24, 2021",J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies,0
"May 24, 2021",A biotech backs off NASH after trial failure,0
"May 24, 2021",Supporting global decentralized and virtual clinical trials during challenging times and beyond,0
"May 19, 2021",Closely watched Bristol Myers immunotherapy shows benefit in melanoma,0
"Updated May 19, 2021",FDA delays a biotech's cancer cell therapy once again,0
"May 18, 2021","Sarepta's Duchenne gene therapy clears study hurdle, although questions linger",0
"May 14, 2021",Fate offers glimpse at 'natural killer' cell therapy for leukemia,0
"May 10, 2021",The use of AI in rare disease has hidden flaws,0
"May 5, 2021","Adagio, flush with cash, launches large study of next-gen COVID-19 antibody",0
"Updated May 4, 2021",A worrisome side effect stalls a closely watched multiple myeloma drug,0
"May 3, 2021",Sarepta's second-gen Duchenne drug shows signs of topping its first,0
"May 3, 2021",How BYOD leads to patient-centric clinical trials,0
"April 30, 2021","Denying problems, AstraZeneca says US coronavirus vaccine filing due within weeks",0
"April 29, 2021",FDA gives first citation to biotech for failure to report clinical trial details,0
"April 29, 2021",A serious side effect puts a biotech's eye gene therapy in limbo,0
"April 27, 2021","Lilly, citing FDA feedback, won't seek speedy approval of Alzheimer's drug",0
"April 26, 2021",FDA lifts hold on UniQure gene therapy study after review of cancer case,0
"April 26, 2021",Vertex moves pain drug into mid-stage testing,0
"April 23, 2021","Coronavirus vaccine makers Oxford, Novavax follow up with a promising malaria shot",0
"April 19, 2021","Positive data in hand, TG Therapeutics readies MS drug for FDA review",0
"April 15, 2021",GSK stops studies testing closely watched cancer immunotherapy,0
"April 13, 2021","Gilead stops Veklury study, citing enrollment challenges, changing treatment",0
"April 12, 2021","Sage, Biogen drug reduces tremors but side effects could limit potential",0
"April 12, 2021","5 takeaways from AACR, one of the year's top meetings on cancer drugs",0
"April 11, 2021",Lilly gene-targeted drug shows potential for use across cancers,0
"April 9, 2021",Researchers lay out hypothesis for rare side effect linked to AstraZeneca vaccine,0
"April 8, 2021",Lilly claims promising finding in failed study of COVID-19 drug,0
"April 6, 2021",New data push a biotech's muscle disease drug closer to a key test,0
"April 5, 2021","Takeda, CSL to end alliance as plasma-based COVID-19 drug fails key test",0
"March 31, 2021","Pfizer, BioNTech's vaccine protects 12- to 15-year-olds from COVID-19 in study",0
"March 30, 2021",A biotech shelves its Huntington's drugs after trial failures,0
"March 25, 2021",Bristol Myers gets late-stage win in test of new type of immunotherapy,0
"Updated March 25, 2021","AstraZeneca, under fire, tries to repair image with new vaccine data",0
"March 24, 2021",Regeneron joins Lilly in proving lower-dose antibody drugs can thwart COVID-19,0
"March 23, 2021",Roche stops giving Huntington's disease drug in closely watched study,0
"March 23, 2021",FDA won't review Novo diabetes drug in latest case of regulatory pushback,0
"March 23, 2021","AstraZeneca may have used 'outdated' data to describe vaccine's efficacy, NIH says",0
"March 22, 2021","Roche immunotherapy notches a win in early lung cancer, pressuring Merck",0
"March 19, 2021","With new results, Sarepta's 2nd gene therapy holds steady",0
"March 18, 2021",A first-of-its-kind mRNA drug falls short in cystic fibrosis,0
"March 18, 2021","Gilead, still aiming at NASH, broadens an alliance with Novo",0
"March 15, 2021",Lilly lays out 2-year plan to gain approval for Alzheimer's drug,0
"March 13, 2021",Detailed Lilly data give mixed picture of Alzheimer's drug's benefit,0
"March 10, 2021",Lilly builds case for COVID-19 drug cocktail with new data,0
"March 9, 2021",Novartis bid to bring rare disease drug to lung cancer hits a roadblock,0
"March 8, 2021",Merck gives an early peek at COVID-19 drug results,0
"March 8, 2021",Crucial data on AstraZeneca's vaccine are coming. Here's what we may learn.,0
"March 4, 2021",Lilly says diabetes shot outperformed rival Novo drug in study,0
"March 4, 2021",Galapagos reports long-awaited safety data for inflammation drug,0
"March 3, 2021","Lilly drug regrows hair in autoimmune disease study, but safety questions linger",0
"March 2, 2021",A closely watched schizophrenia drug fails key test,0
"Updated March 1, 2021",A play-by-play of the FDA meeting on J&J's vaccine,0
"Updated Feb. 25, 2021","Moderna, Pfizer ready multi-pronged plans for coronavirus variants",0
"Feb. 24, 2021",Icon to buy contract researcher PRA Health for $12B,0
"Updated Feb. 24, 2021","FDA review supports safety, efficacy of J&J coronavirus vaccine",0
"Feb. 22, 2021",FDA lays out shortened path for testing vaccines against new coronavirus variants,0
"Feb. 22, 2021",Sanofi and GSK start trial of upgraded coronavirus vaccine after first version disappoints,0
"Updated Feb. 23, 2021",Why this week's FDA meeting on J&J's coronavirus vaccine will be important,0
"Feb. 16, 2021",10 biotechs become 1: Centessa launches with $250M to prove unorthodox R&D model,0
"Feb. 16, 2021",eReconciliation tool: A new software to facilitate Safety Data Reconciliation between clinical and safety databases,0
"Feb. 11, 2021","AstraZeneca plans for adapting vaccine to coronavirus variants, but offers longer timeline than rivals",0
"Feb. 11, 2021","Gilead, Galapagos halt development of experimental drug, denting research alliance",0
"Feb. 11, 2021","In surprise finding, Roche arthritis drug cuts risk of COVID-19 death in large UK study",0
"Feb. 9, 2021",Small biotech gets big win on treatment for rare swelling disorder,0
"Feb. 8, 2021",New data on AstraZeneca vaccine add to worries over coronavirus variant from South Africa,0
"Feb. 5, 2021",PTC aims again for FDA review of Duchenne drug despite latest miss,0
"Feb. 4, 2021","UK to start study testing Pfizer, AstraZeneca vaccines together",0
"Feb. 1, 2021",Breaking down the barriers to decentralized trials,0
"Updated Jan. 29, 2021",Amgen study data bolster prospects of KRAS-blocking cancer drug,0
"Jan. 27, 2021","Lilly allies with Vir, GSK as coronavirus variants raise worries about antibody drugs",0
"Jan. 26, 2021","Can new Regeneron, Lilly data move the needle for COVID-19 antibody drugs?",0
"Jan. 26, 2021",J&J says study data on coronavirus vaccine due 'early next week',0
"Jan. 25, 2021","AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica",0
"Jan. 25, 2021",Moderna to study vaccine booster aimed at coronavirus variant,0
"Jan. 25, 2021",Merck stops coronavirus vaccine development in surprise setback,0
"Jan. 20, 2021","Lilly's antibody drug prevents COVID-19 in study, but hurdles to use remain",0
"Jan. 20, 2021","Pfizer, BioNTech say vaccine effective against fast-spreading UK coronavirus variant",0
"Jan. 19, 2021",Biohaven adds to a long list of Alzheimer's drug failures,0
"Jan. 11, 2021",10 key clinical trials to watch in the first half of 2021,0
"Jan. 7, 2021",Pfizer beats Sarepta to start of first late-stage Duchenne gene therapy trial,0
"Dec. 22, 2020","Amgen's asthma drug takes a hit, making for stiffer competition with Regeneron",0
"Dec. 21, 2020","With biosimilars looming, Roche makes case for new biologic eye drug",0
"Updated Dec. 17, 2020",FDA panel endorses Moderna's coronavirus vaccine,0
